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ACS Acute Coronary Syndrome
AF Atrial Fibrillation
ANNEXA(TM) Andexanet Alfa a Novel Antidote to the
Anticoagulant Effects of factor XA Inhibitors
APPRAISE-1 Apixaban for Prevention of Acute Ischemic
and Safety Events
aPTT activated partial thromboplastin time
ARISTOTLE Apixaban versus Warfarin in Patients with
Atrial Fibrillation
ATLAS ACS-TIMI 46 Anti-Xa therapy to lower cardiovascu-
lar events in addition to aspirin with/without
thienopyridine therapy in subjects with acute coro-
nary syndrome
AVERROES trial Apixaban Versus Acetylsalicylic Acid to
Prevent Stroke in Atrial Fibrillation Patients
CHADS2 Congestive Heart Failure Hypertension Age
Diabetes Stroke
CHADS2-VASC Congestive Heart Failure Hypertension Age
Diabetes Stroke-Vascular disease, Age, Sex
ECT Ecarin clotting time
ENGAGE AF-TIMI 48 Effective Anticoagulation with Factor
Xa Next Generation in Atrial Fibrillation-Throm-
bolysis in Myocardial Infarction 48
ESTEEM Effect of Ximelagatran on Ischemic Events and
Death in Patients With Atrial Fibrillation After
Acute Myocardial Infarction in the Efficacy and
Safety of the Oral Direct Thrombin Inhibitor
Ximelagatran
EXPLORE-Xa Phase II study of the safety, tolerability and
pilot efficacy of oral factor Xa inhibitor betrixaban
compared with warfarinIntroduction
Historical background
‘‘The can of un-coagulated blood lying on the
floor of Link’s laboratory was to change the course
of history, and little did Link know what the
long-term implications would be’’ [1]. In 1941,
the Wisconsin Alumni Research Fund (WARF)
scientist Karl Paul Link and his senior student
Wilhelm Schoeffel could never have imagined
that their research would live longer than 73 years.
Link named the substance after the organization
that supported his research and the name war-
farin was created (Fig. 1). In the 1950s, warfarin
was used as an anticoagulant for victims of heart
attacks and strokes. It gained fame when it was
used to treat President Dwight D. Eisenhower
after his 1955 coronary event while in office [1].
The historical narrative of warfarin starts with a
mysterious hemorrhagic disease (sweet clover
disease) of cattle to the development of a rat
poison (rodenticide), which later became one of
the most commonly prescribed drugs in the
history of mankind.
Warfarin is a highly effective treatment for the
reduction of stroke in atrial fibrillation (AF) and
its limitations are well studied. Over the last
FDA Food and Drug Agency
GLORIA-AF The Global Registry on Long-Term Oral
Antithrombotic Treatment in Patients with Atrial
Fibrillation
INR International normalized ratio
NOACs Novel oral anticoagulants
PCC Prothrombin concentrated complex
PCI Percutaneous coronary intervention
Pioneer AF-PCI A Study Exploring Two Strategies of
Rivaroxaban and One of Oral Vitamin K Antagonist
in Patients With Atrial Fibrillation Who Undergo
Percutaneous Coronary Intervention
PT Prothrombin time
REDEEM Dose finding study for dabigatran etexilate in
patients with acute coronary syndrome
RUBY-1 Study evaluating safety, tolerability and efficacy of
darexaban in subjects with acute coronary
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ANNIVERSARY OF HISTORICAL WARFARIN70 years, warfarin use has been associated with
extreme clinical problems for patients, patients’
family, healthcare providers, and healthcare
systems (bleeding, visits to emergency, hospital-
izations/costs, length of stay, multiple interna-
tional normalized ratio (INR) tests, variability in
response, commercial variability on generics and
others [2]. In a historical cohort analysis, switching
warfarin formulations was found to expose
patients with AF to a higher risk of bleeding
events compared to remaining on a single prod-
uct. Research found that maintaining patients on
a product with consistent bioavailability may
optimize the risk-benefit balance of anticoagula-
tion therapy [3].syndromes
RE-VERSE AD trial A Study of the RE-VERSal Effects of
Idarucizumab on Active Dabigatran trial
RE-LY Randomized Evaluation of Long-Term Anticoagu-
lant Therapy
ROCKET-AF The Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation
TCT Thrombin clotting time
WARF Wisconsin Alumni Research Fund
VTE Venous thromboembolism
VKA Vitamin K antagonistThe scope of novel oral anticoagulants (NOACs)
In the last few years, emerging novel or new oral
anticoagulants referred to as novel oral anticoagu-
lants or NOACs (comprising apixaban (Eliquis),
edoxaban (Lixiana), rivaroxaban (Xarelto) factor
Xa inhibitors, and dabigatran (Pradaxa) direct
thrombin inhibitor) have been used in patients
with non-valvular atrial fibrillation as suitable
alternatives to the perpetual warfarin and ana-
logues (vitamin K antagonists or VKAs) to prevent
stroke and venous thromboembolism (VTE). The
major trials of NOACs in AF were: ARISTOTLE,
ENGAGE-AF, Rocket-AF and RE-LY, respectively
[4–7]. NOACs are presently contraindicated in
patients with mechanical heart valves, following
several reports of valve thrombosis.Figure 1. Karl link promoting warfarin as a rodenticide (courtesy of
University of Wisconsin).It is prudent for physicians and patients to dis-
cuss concerns associated with NOACs in order
to ensure the safe and effective use of these drugs
in specific clinical situations. Clinical scenarios
should emphasize the practical start-up and fol-
low-up schemes for patients on NOACs, as the
procedure for switching between anticoagulantFigure 2. Karl link in his laboratory (courtesy of University of
Wisconsin).
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measuring and monitoring the anticoagulant
effect of NOACs should also be standardized
(see Fig. 2).
The management of bleeding and steps to follow
thereafter should be well-elucidated when there is
a (suspected) overdose without bleeding, or a clot-
ting test indicating a risk of bleeding. The man-
agement of bleeding complications is crucial to
NOAC therapy patients undergoing a planned
surgical intervention or ablation, and patients
undergoing an urgent surgical intervention.
Special populations (such as patients with
chronic kidney disease, AF, and coronary artery
disease) or patients treated with NOACs (cardio-
version in a NOAC-treated patient, patients
presenting with acute stroke while on NOACs,
NOACs versus VKAs in AF patients with a malig-
nancy) should be addressed clearly in guidelines
and management plans. Besides, drug–drug
interactions and pharmacokinetics of NOACs
and issues of adherence to NOACs intake, how
to deal with dosing errors, and missed doses are
also of critical clinical concerns.
Disadvantages associated with the use of NOACs
The most common disadvantage of NOACs is
the lack of an antidote to resolve major bleeding
complications possibly associated with their ubiq-
uitous use. Another major concern is the peripro-
cedural management of patients on NOACs which
is a common complex clinical problem and may
pose a patient-specific concern. The third disad-
vantage is cost of each NOAC calculated as total
daily cost and in comparison with warfarin.
Furthermore, therapeutic monitoring may impact
patient adherence, hence should not be used in
patients with a history of medication non-adher-
ence. Most NOACs are renal eliminated, therefore
patients with renal impairment <30 mL/min will
not have the chance to benefit from full clinical
utility.
The rationale
In day-to-day clinical practice, the use of war-
farin poses several limitations. NOACs represent
an archetypal shift in the management of
non-valvular AF. NOACs are more specific and
possess rapid onset of action with predictable
pharmacokinetic profile (fixed dosing and no
coagulation monitoring). NOACs have been used
with certain concerns such as drug interactions,
switch-therapy, patient selection, renal impair-
ment, therapeutic drug monitoring, risk of
myocardial infarction, use in patients with acutecoronary syndrome (ACS) requiring antiplatelet
therapy, such as cardioversion and percutaneous
coronary intervention (PCI).
NOACs are not well utilized in patients with AF
despite their approved indications by the Food
and Drug Agency (FDA) and an array of published
literature supporting their clinical utility, safety,
and efficacy. However, other aspects of NOACs
such as cost, therapeutic drug monitoring, selec-
tion of NOAC, patient satisfaction and quality of
life deserve further emphasis and research.
Review summary
NOACs are currently widely used for the pre-
vention of stroke and systemic embolism in
patients with non-valvular AF, with ubiquitous
alternatives for patients using warfarin. This over-
view offers insights into the clinical utility of
NOACs with emphasis on pivotal clinical trials
that provide the basis for NOAC safety and effi-
cacy. This overview will address the issues of con-
cerns and problematic areas encountered in real
world clinical practice.
Objective of review
We sought to investigate the clinical utility of
NOACs and provide some insights into their use-
fulness. The main objective was to raise awareness
among clinicians regarding the under-utilization
of NOACs and to encourage the use of NOACs
in daily clinical practice as suitable alternatives
to warfarin.Methods
We retrieved the literature for publications per-
taining to NOACs. Relevant studies were reported
to a citation manager and were read and studied
by the research team. We reviewed most of the
clinical trials performed on NOACs. The search
engine used for NOAC clinical trials included:
PubMed, Medline, Scopus, Google Scholar and
Cochrane Library. The following medical sub-
headings and keywords were used for searching:
novel oral anticoagulants (NOACs), atrial fibrilla-
tion, dabigatran, apixaban, rivaroxaban, edoxa-
ban, warfarin, non-valvular atrial fibrillation,
NOAC bleeding, NOAC efficacy and safety,
NOAC clinical utility, NOAC therapeutic drug
monitoring, and NOAC antidote.
The types/features of NOACs
The choice between all four NOACs depends on
patient characteristics (such as age), cost, insur-
ance schemes, reversal of bleeding, patient’s renal
R
EV
IE
W
 A
RT
IC
LE
J Saudi Heart Assoc
2016;28:31–45
SHEHAB ET AL 35
NOVEL ORAL ANTICOAGULANTS AND THE 73RD
ANNIVERSARY OF HISTORICAL WARFARINfunction, renal dosing [8], dosing interval, medica-
tion patients are on, drug interactions, and patient
preferences rather than safety profiles. All are
more or less similar, but nevertheless, no detailed
comparison has been performed between the var-
ious NOACs. One obstacle of paramount impor-
tance to the utilization of NOACs is the reversal
of bleeding, but possible solutions are on the hori-
zon for a new antidote for dabigatran, which is on
its way to clinicians for routine monitoring.NOACs and clinical evidence
The first randomized trial of anticoagulants
nicoumalone and heparin was performed in 1960
[9]. Since then, a plethora of studies has been con-
ducted on acenocoumarol, dicoumarol, and later
warfarin. From randomized trials to observational
studies, the literature today is replete with evi-
dence regarding the use of NOACs.
A recent network meta-analysis (indirect com-
parison) published in the May 2014 issue of
Thrombosis and Haemostasis compared the efficacy
and safety of edoxaban with other NOACs. The
study found some differences among NOACs,
allowing treatment selections according to the
clinical profile of each patient. Indirect compar-
isons of efficacy endpoints demonstrated that
high-dose edoxaban was comparable to dabiga-
tran 110 mg twice, yet inferior to dabigatran
150 mg. Moreover, high-dose edoxaban was com-
parable in efficacy to apixaban; however, apixaban
had fewer bleeding endpoints [10].
Efficacy of low-dose edoxaban was either similar
or less effective than its competitors. When safety
endpoints were compared, low-dose edoxaban
emerged as the most efficient, with the least
bleeding. The differences among the drugs also
suggest that patient-related factors, such as
expected compliance, individual focus on efficacy
and side-effects as well as renal function, should
be taken into account when selecting a drug. The
limitation of this study is that the findings, similar
to previous indirect comparisons of NOACs, are
not based on direct head-to-head comparisons
(which remain the gold standard), and thus need
to be considered with some caveats [10].
The safety of NOACs was compared to warfarin
in patients with AF in randomized trials using sys-
tematic reviews and meta-analyses in 2012. In the
prevention of stroke and systemic embolism in
patients with AF, NOACs demonstrated more effi-
cacy than warfarin. This was evident in the
decreased risk for intracranial bleeding and favor-
able safety profile in favor of patients using
NOACs [11].The benefits and harms of NOACs versus war-
farin for AF and VTE were compared in a system-
atic review from 2001 through to July 2012.
NOACs were reported as feasible options for
patients receiving long-term anticoagulation. The
magnitude of treatment benefits compared with
warfarin are small and vary depending on the
control achieved by warfarin treatment. It has
been reported that there were no head-to-head
comparisons of NOACs and that limited data
was reported on harmful effects [12].
A meta-analysis by Gómez-Outes and col-
leagues analyzed the safety and efficacy of three
oral anticoagulants [13]. In all three NOAC types,
more than 50,000 patients were included in the
analysis. The three NOACs demonstrated a simi-
lar efficacy in the prevention of non-hemorrhagic
stroke when compared to warfarin in non-valvular
AF. Each of the respective pivotal trials indicated
an overall statistically significant reduction in all
strokes, both hemorrhagic and ischemic compared
to warfarin. These conclusions were supported by
two other meta-analyses [10,14].
In the absence of head-to-head comparison, an
analysis was performed to compare NOACs with
VKAs and NOACs indirectly with each other.
The results revealed no differences between
NOACs and VKA regarding recurrent VTE
and death. Bleeding was significantly reduced
by NOACs (apixaban < rivaroxaban < dabiga-
tran < edoxaban). Regarding efficacy, no differ-
ences were found between NOACs. Apixaban
was more successful at reducing incidence of
major bleeding than dabigatran and edoxaban.
Regarding occurrence of the composite bleeding
endpoint, apixaban performed better than all
other NOACs and dabigatran performed better
than rivaroxaban and edoxaban. The authors con-
cluded that NOACs are as efficient in the treat-
ment of VTE as VKA but with reduced risk of
bleeding complications. Indirect comparisons
indicate differences in the risk of clinically
relevant bleeding events. NOACs increased the
therapeutic spectrum and thereby the potential
for individualized therapy [15].Advantages of NOAC therapy over warfarin
The use of NOAC when compared to warfarin is
associated with both cons and pros. The limita-
tions of warfarin use are well established.
However, warfarin is highly effective when used
optimally, is well established and accepted, and
is inexpensive (although monitoring and adverse
reactions are an enormous burden to the
Table 1. Comparison of Pharmacological Characteristics of Warfarin and NOACs for Atrial Fibrillation.
NOAC Trade
Mark
(proprietary
name)
Warfarin
(Coumadin) 1 mg
to 10 mg
Dabigatran (Pradaxa) 75, 110,
150 mg
Rivaroxaban (Xalerto) 10, 15,
20 mg
Apixaban (Eliquis) 2.5,
5 mg
Edoxaban (Savaysa) 30, 40, 60 mg
Drug class Vitamin K
antagonist
Direct Thrombin Inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor
Approved
indications
Stroke prevention
in valvular and
NVAF, VTE
treatment; VTE
prevention
Stroke prevention in NVAF, VTE
treatment; VTE prevention
Stroke prevention in NVAF;
VTE treatment, recurrent VTE
prevention, prophylaxis of
VTE following hip/knee
replacement
Stroke prevention in
NVAF, prophylaxis of
VTE following hip/knee
replacement
To reduce risk of stroke and
systemic embolism (SE) in patients
with NVAF, VTE treatment
Time to peak
effect
3–5 days 1 hour 2.5– 4 h 3 h 1–2 hour(s)
Bioavailability
(%)
79–100 3-7 80-100 50 62
Half-life (hours) 40 12–17 5–9 8–15 9–11
Renal
elimination
(%)
>90 >80 66 25–27 50
Dosing
frequency
Once a day Twice a day Once a day Twice a day Once a day
Dosing in AF Variable
depending on
INR adjustment
(2-3 in non-
valvular AF and
2-3.5 in valvular
AF)
150 mg twice daily (Cr Cl >30 mL/
min)
75 mg twice daily (Cr Cl 15-30 mL/
min)
15 mg once daily
(Cr Cl 15–50 mL/min)
2.5 mg twice daily if (age
>80, body weight <60 kg,
serum creatinine
133 lmol/L = >1.5 mg/
dL)
30 mg or 60 mg every day (with
adjustment for high exposure).
Recommended dose is 60 mg once
daily in patients with Cr CL >50 to
695 mL/min. Do not use
SAVAYSA in patients with Cr CL
>95 mL/min
Reduce dose to 30 mg once daily in
patients with Cr CL 15 to 50 mL/
min
Effect on
coagulation
tests
" PT ": TCT, ECT, aPTT
"or no change: PT
"Anti-factor Xa
"or no change: PT, aPTT
No change: TCT, ECT
"Anti-factor Xa
"or no change: PT, aPTT
No change: TCT, ECT
"Anti-factor Xa
"or no change: PT, aPTT
No change: TCT, ECT
Anticoagulation
monitoring
Required Not required Not required Not required Not required
Specific antidote Vitamin K Idaricuzumab Andexanet Andexanet Andexanet
Reversal in
emergency
bleeding
Application of
FFP and platelets
usually resolves
the situation
Oral charcoal
Hemodialysis
PCC
Desmopressin
Antifibrinolytic agents
Application of FFP and platelets
usually resolves the situation
PCC
Desmopressin
Antifibrinolytic agents
Application of FFP and
platelets usually resolves the
situation
PCC
Desmopressin
Antifibrinolytic agents
Application of FFP and
platelets usually resolves
the situation
Hemodialysis does not
significantly contribute to
edoxaban clearance. Protamine
sulfate, vitamin K, and tranexamic
acid are not expected to reverse
anticoagulant activity
Application of FFP and platelets
usually resolves the situation
REVIEW ARTICLE
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NOVEL ORAL ANTICOAGULANTS AND THE 73RD
ANNIVERSARY OF HISTORICAL WARFARINhealthcare system and to many patients). In order
for a NOAC to become a first choice for patients, it
must be more convenient (an advantage that may
also amplify adherence and diligence) and, more-
over, it will need to deliver better clinical out-
comes, at a satisfactory cost, with uniformity
across the major subgroups of patients.Dabigatran
Dabigatran, a direct thrombin inhibitor, was the
first FDA-approved NOAC. The Randomized
Evaluation of Long-Term Anticoagulant Therapy
(RE-LY) trial, a non-inferiority randomized trial
with open-label warfarin that included 18,113
patients with AF and at least one risk factor for
stroke, demonstrated that dabigatran was as safe
and effective as warfarin. Dabigatran 150 mg was
superior to warfarin in reducing the incidence of
stroke (including hemorrhagic) and systemic
embolism by 34% (p < 0.001) with no significant
difference in major bleeding. Dabigatran 110 mg
was non-inferior to warfarin in preventing stroke
and systemic embolism, and was associated with
a 20% relative risk reduction in major bleeding
compared to warfarin (p = 0.003). Gastrointestinal
bleeding was more common with higher-dose
dabigatran than warfarin, and dyspepsia was
more common with dabigatran (11.8% of patients
with 110 mg and 11.3% of patients with 150 mg
compared to 5.8% with warfarin; p < 0.001 for
both) [7]. Apart from bleeding, a very common
side effect of dabigatran is dyspepsia. This is
probably due to the presence of tartaric acid in
the capsule which is intended to improve absorp-
tion. The use of proton pump inhibitors (PPIs) or
ranitidine may be indicated to overcome this.
The main concerns are renal dosing, increased
bleeding, and the lack of an approved antidote.
In 2011, the EudraVigilance dataset reported 256
cases of serious bleeding resulting in death
associated with the use of dabigatran [16]. The
FDA investigation concluded there was no
evidence that bleeding rates were higher with
dabigatran compared to other NOACs.
Dabigatran increases thrombin clotting time
(TCT), ecarin clotting time (ECT), and activated
partial thromboplastin time (aPTT); it may or
may not increase prothrombin time (PT).
Currently, an antidote is in phase II with ongoing
trials. Reversal of bleeding can be accomplished
by oral charcoal, haemodialysis, and prothrombin
complex concentrate (PCC), desmopressin and
antifibrinolytic agents (Table 1).
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2016;28:31–45Rivaroxaban
The study entitled ‘Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation
(ROCKET-AF)’ is a double-blind, randomized
comparison of rivaroxaban 20 mg once daily (with
dose adjustment for renal function) versus dose-
adjusted warfarin (INR target between 2.0 and
3.0, which was achieved at a median time of
58%). The trial targeted high-risk patients with a
congestive heart failure hypertension age diabetes
stroke (CHADS2) score of P2, and approximately
half had history of prior stroke. There was a 12%
relative risk reduction in the occurrence of stroke
and systemic embolism in AF patients treated
with rivaroxaban that did not reach statistical
significance but was clearly non-inferior to war-
farin. Similar to dabigatran, there were significant
reductions in intracranial hemorrhage; however,
there was a higher incidence of major gastroin-
testinal bleeding when compared to patients in
the warfarin cohort [6]. Rivaroxaban increases
anti-factor Xa, may or may not increase PT and
aPTT, and has no effect on TCT or ECT. Reversal
of emergency bleeding can be with PCC, desmo-
pressin or antifibrinolytic agents (Table 1).
Apixaban
The Apixaban versus Warfarin in Patients with
Atrial Fibrillation (ARISTOTLE) trial compared
apixaban with warfarin for the prevention of stroke
and systemic embolism in patients with AF and at
least one additional risk factor for stroke.
Compared with warfarin, apixaban reduced stroke
and systemic embolism by 21% (p = 0.01), resulted
in 31% less bleeding (p < 0.001), and 11% lower
mortality (p = 0.047). Apixaban was better tolerated
than warfarin, with fewer drug discontinuations
[4]. The ARISTOTLE trial demonstrated that apix-
aban is not only more effective than warfarin at
preventing stroke, but also safer in terms of bleed-
ing risk and risk of death.
In the AVERROES trial (apixaban versus acetyl-
salicylic acid to prevent stroke in AF patients who
have failed or are unsuitable for VKA treatment),
apixaban was compared to aspirin alone for stroke
prevention [17]. The trial was terminated early
due to a clear, overwhelming demonstration of
anticoagulation benefit in the apixaban cohort.
The rate of major bleeding in the apixaban group
was similar to that seen in the ARISTOTLE trial.
Apixaban increases anti-factor Xa, may or may
not increase PT and aPTT, and has no effect on
either TCT or ECT. Reversal of emergencybleeding can be with PCC, desmopressin or
antifibrinolytic agents (Table 1).Edoxaban
The Effective Anticoagulation with Factor Xa
Next Generation in Atrial Fibrillation (ENGAGE
AF-TIMI 48) trial has randomized >20,000 patients
who have AF and a CHADS2 score ofP2. Patients
were randomized in a double-blind fashion to
warfarin (target INR, 2.0–3.0) or one of two doses
of edoxaban given once daily, with dose adjust-
ments both at baseline and subsequently for
factors associated with higher drug exposure,
including renal insufficiency [11]. The trial con-
cluded that both once-daily regimens of edoxaban
were non-inferior to warfarin with respect to the
prevention of stroke or systemic embolism and
were associated with significantly lower rates of
bleeding and death from cardiovascular causes
(Table 1). Hemodialysis does not significantly
contribute to edoxaban clearance. Protamine
sulfate, Vitamin K, and tranexamic acid are not
expected to reverse anticoagulant activity.
NOACs have been shown to be convenient,
carry important advantages in improving clinical
outcomes, including fewer strokes, have fewer
events of intracranial hemorrhage, and lower mor-
tality. These benefits are consistent in warfarin
naive or warfarinized patients. Furthermore, the
cost is somewhat acceptable, particularly in light
of the major advantage with regard to conve-
nience (Tables 1 and 2).New indications for NOACs
More recently over the last four years, studies
have targeted NOACs combined with antiplatelet
treatment for patients with a recent ACS in an
effort to reduce ischemic events. A meta-analysis
was performed to evaluate the efficacy and safety
of adding NOACs to single (aspirin) or dual
(aspirin and clopidogrel) antiplatelet therapy.
The following were included in the trials:
Esteem, Appraise-1, Atlas ACS-TIMI46, Redeem,
Ruby-1, Appraise-2, and Atlas ACS2-TIMI51
[4,6,7,18–20].
The addition of a NOAC to antiplatelet therapy
in patients with a recent ACS in a meta-analysis
showed modest reduction in cardiovascular
events but a substantial increase in bleeding, most
pronounced when NOACs were combined with
dual antiplatelet therapy. It has been found that
the randomized trials included in the meta-
analysis were under-powered for the evaluation
of efficacy [21].
REVIEW ARTICLE
Table 2. Results of large randomized clinical trials of NOACs versus warfarin.
Clinical events
Novel drug and dose NOAC Warfarin Hazard ratio (95% CI) P (Superiority)
Stroke or systemic embolism, percentage/year
RE-LY Dabigatran 110 mg twice a day
Dabigatran 150 mg twice a day
1.53
1.11
1.69
1.69
0.91 (0.74–1.11)
0.66 (0.53–0.82)
0.34
<0.001
ROCKET-AF Rivaroxaban 20 mg every day 2.12 2.42 0.88 (0.75–1.03) 0.12
ARISTOTLE Apixaban 5 mg twice a day 1.27 1.60 0.79 (0.66–0.95) 0.01
ENGAGE AF-TIMI 48 Edoxaban 60 mg
Edoxaban 30 mg
1.18
1.61
1.50 0.79 (0.63–0.99)
0.87
1.07 (0.87–1.31)
1.13
<0.001 for non-inferiority, 0.017 for superiority
0.005 for non-inferiority, 0.44 for superiority
Hemorrhagic stroke, percentag/year
RE-LY Dabigatran 110 mg twice a day
Dabigatran 150 mg twice a day
0.12
0.10
0.38
0.38
0.31 (0.17–0.56)
0.26 (0.14–0.49)
<0.001
<0.001
ROCKET-AF* Rivaroxaban 20 mg every day 0.26 0.44 0.59 (0.37–0.93) 0.02
ARISTOTLE Apixaban 5 mg twice a day 0.24 0.47 0.51 (0.35–0.75) <0.001
ENGAGE AF-TIMI 48 Edoxaban 60 mg
Edoxaban 30 mg
0.54
0.33
0.26
0.16
0.54 (0.38–0.77)
0.33 (0.22–0.50)
<0.001
<0.001
Ischemic or uncertain stroke, percentage/year
RE-LY Dabigatran 110 mg twice a day
Dabigatran 150 mg twice a day
1.34
0.92
1.20
1.20
1.11 (0.89–1.40)
0.76 (0.60–0.98)
0.35
0.03
ROCKET-AF* Rivaroxaban 20 mg every day 1.34 1.42 0.94 (0.75–1.17) 0.58
ARISTOTLE Apixaban 5 mg twice a day 0.97 1.05 0.92 (0.74–1.13) 0.42
ENGAGE AF-TIMI 48 Edoxaban 60 mg
Edoxaban 30 mg
1.0
1.73
1.76
2.48
0.80 (065–098)
1.10 (091–1.32)
0.97
<0.001
Major bleeding, percentage/year
RE-LY Dabigatran 110 mg twice a day
Dabigatran 150 mg twice a day
2.71
3.11
3.36
3.36
0.80 (0.69–0.93)
0.93 (0.81–1.07)
0.003
0.31
ROCKET-AF* Rivaroxaban 20 mg every day 3.60 3.45 1.04 (0.90–1.20) 0.58
ARISTOTLE Apixaban 5 mg twice a day 2.13 3.09 0.69 (0.60–0.80) <0.001
ENGAGE AF-TIMI 48 Edoxaban high dose
Edoxaban low dose
2.75
1.61
1.76
1.73
0.80 (0.71–0.91)
0.47 (0.41–0.55)
<0.001
<0.001
Death, percentage/year
RE-LY Dabigatran 110 mg twice a day
Dabigatran 150 mg twice a day
3.75
3.64
4.13
4.13
0.91 (0.80–1.03)
0.88 (0.77–1.00)
0.13
0.051
ROCKET-AF Rivaroxaban 20 mg every day 4.5 4.9 0.92 (0.82–1.03) 0.15
ARISTOTLE Apixaban 5 mg twice a day 3.52 3.94 0.89 (0.80–0.998) 0.047
ENGAGE AF-TIMI 48 Edoxaban high dose
Edoxaban low dose
3.43
1.61
3.17
2.71
0.86 (0.77–0.97)
0.85 (0.76–0.96)
0.003
0.021
Keys: NOACs = Novel Oral Anticoagulants, RE-LY = Randomized Evaluation of Long-Term Anticoagulant Therapy, ROCKET-AF = Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared
With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation, ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation.
* On-treatment population, ENGAGE AF-TIMI 48 = Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
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J Saudi Heart Assoc
2016;28:31–45The PIONEER AF trial is an exploratory, open-
label, randomized, multicenter, clinical study
assessing the safety of two rivaroxaban treatment
strategies and one VKA treatment strategy in
approximately 2100 subjects who have paroxys-
mal, persistent, or permanent non-valvular AF,
and have PCI with stent placement. The results
of this study will be announced in 2016.
Further, NOACs have been used in the area of
organ transplantation as prophylactic or thera-
peutic options. One study reports on a series of
heart transplant recipients treated with rivaroxa-
ban and followed at a transplantation center [22].
Evidence has emerged suggesting that factor Xa
and thrombin are involved in other physiological
and pathophysiological cellular processes, includ-
ing inflammation [23]. Preclinical studies have
demonstrated that targeted inhibitions of factor
Xa or thrombin exhibit effects beyond coagulation,
such as anti-inflammation and potential influence
on the progression of atherothrombosis [24–26],
although supporting clinical data are currently
lacking.Discussions
The main objective of this overview is to raise
clinician awareness of the under-utilization of
NOACs and shed light on the main concerns
surrounding their clinical utility as suitable
alternatives to warfarin.The convenience of NOACs
NOACs are far more convenient than warfarin
because they have predictable pharmacodynamic
effects, and, at doses tested in large trials, have
good efficacy and safety profiles without the need
for anticoagulation monitoring, or for frequent
dose adjustment that may contribute to dosing
errors and missed doses. Dabigatran and apixa-
ban are administered twice a day. Rivaroxaban
and edoxaban are given once a day. NOACs have
the advantage of rapid onset of action and rela-
tively short half-life periods, making their use
around the time of procedures more convenient
than warfarin, without the need for bridging [27].NOACs efficacy outcomes
NOACs are at least as good as warfarin at
preventing stroke, and there is major benefit in
outcome compared to no therapy. Dabigatran
150 mg twice daily and apixaban 5 mg twice daily
are more effective than warfarin in terms of
preventing stroke [27].NOACs safety outcome
With dabigatran, apixaban and rivaroxaban, the
rate of hemorrhagic stroke is reduced by 40% to
70% and that of intracranial hemorrhage by 50%,
which suggests a liability for warfarin with regard
to intracranial hemorrhage. Both lower doses of
110 mg / 75 mg for Dabigatarn and 2.5 mg for
Apixaban have resulted in crucial reductions in
major bleeding. Such vital improvements in clinical
outcomes have provided the most compelling ratio-
nale for the use of NOACs as first-line agents [27].
NOACs effect on mortality
The use of apixaban, dabigatran and rivaroxa-
ban have resulted in an 10% reduction in mortal-
ity, although this reached statistical significance
only for apixaban. The fact that mortality tends
to be lower suggests that, overall, the clinical ben-
efits of NOACs clearly outweigh the risks [27].
Switching from warfarin to NOACs
Reports suggest that although NOACs provide
significant benefits for patients not previously on
warfarin, there is little advantage to switching to
NOACs if patients are tolerating warfarin and
maintaining INR control (Not evident with
research study). The benefits of NOACs were sim-
ilar, not considering prior warfarin [5]. Centers
with INR control report that with dabigatran there
was no statistically significant evidence of less
benefit of stroke prevention. Importantly, the ben-
efits of dabigatran over warfarin in reducing
intracranial hemorrhage appeared to be nearly
indistinguishable across INR control ranges. On
the other hand, the pattern of a consistent benefit
despite INR control was relevant with rivaroxaban
and apixaban [27].
The advantages of switching from warfarin to
NOACs include more stable anticoagulation (in
patients poorly controlled on warfarin), short half-
life, the elemination of anticoagulant monitoring,
fewer drug–drug interactions, fewer food–drug
interactions and less intracranial bleeding. The
disadvantages include: specific antidote so not
reversible in bleeding patients or those requiring
emergency surgery. Further, there is an increased
frequency of gastrointestinal bleeding with dabiga-
tran and rivaroxaban compared to warfarin.
NOACs should be considered in patients
switching from warfarin due to poor INR control
despite good compliance, patients with newly
diagnosed non-valvular AF (apixaban and dabiga-
tran, but not rivaroxaban). NOACs have slightly
different properties and the best choice of agent
may depend on individual patient characteristics.
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of clinical practice
There are three integrated grey areas in the
selection battle between warfarin and NOACs,
and in light of the randomized clinical trials,
meta-analyses, these areas require discussion.The selection of patient suitability for NOACs
A determining factor for patient suitability to
NOAC is demographics (age), co-morbidities
(chronic kidney disease, history of bleeding),
degree of renal impairment (creatinine clearance
>30 mL/min), adherence to daily dosing, cost,
insurance schemes, unstable INR, unwillingness
to take warfarin, stroke risk (CHADS2-VASC
score) and risk of bleeding. Renal impairment is
crucial for selection of NOAC; for instance,
dabigatran should not be used in patients with
creatinine clearance <30 mL/min, while rivaroxa-
ban, apixaban and dabigatran are contraindicated
in patients with creatinine clearance <15 mL/min.
NOACs are not approved for use in dialysis
patients. Patients with a history of stroke or
bleeding complications are more likely to be
switched from VKA to NOAC.NOACs from a patient’s perspective
A recent study with unique experimental results
in an assessment of the relative value and weight
of clinical events associated with anticoagulant
therapy concluded that not all outcomes are cre-
ated equal in the minds of patients [28]. The study
showed that patients valued the taking of drugs
that carried a lower risk of fatal bleeding, report-
ing they were willing to accept a 2.8% risk of
nonfatal stroke, a 2.2% risk of nonfatal myocardial
infarction, and a 3.4% risk of cardiovascular death
to avoid a 1% risk of fatal bleeding. NOACs are
characterized by their efficacy outcomes (reduc-
tion in major cardiovascular events) and the
likelihood of side effects (risk of minor, major,
or fatal bleeding). The decision on choice of drug
to take, implicit in that decision, is the relative
weight the authors relate to clinical outcomes.
This weight was assumed to be different
from patient to patient or from physician to
physician [28].
The finding that patients prefer a NOAC to
warfarin relies solely on the basis of its ‘newness’
and not necessarily due to any conferred benefit
‘‘suggests that labels can influence patients’
medication choices’’ and ‘‘should be used with
caution in the shared decision-making process.’’
Overall, patients are not particularly concernedabout the need for monitoring with warfarin.
The preference for ‘‘avoiding the inconvenience
of INR monitoring is trivial when compared with
a preference for avoiding clinical outcomes [28].
The economic burden of NOACs
There are growing concerns that patients do not
take medications when cost of medications surge
beyond their budgets. Most patients with AF have
co-morbidities with problematic poly-pharmacy
issues. The cost of multi-drug pill can go very high
with NOAC and the result can be devastating to
the patient and healthcare system.
High medication costs also diminish hospital
revenues and impact on their ability to keep up
with the flow of very expensive remedies entering
the market. Insurance coverage is another impact
factor that faces developing, underdeveloped and
even developed countries (in the USA, the Patient
Protection and Affordable Care Act, aka
ObamaCare, may overcome this). The cost of
NOACs will be part of a high pill for a co-morbid
elderly patient mostly a retired person. The impli-
cations of cost on NOAC selection is considered
highly significant for clinicians.
The selection of NOACs
The issue of dosing plays a major part in the
selection of NOAC from the four available patent
compounds. Dabigatran and apixaban are taken
in a twice daily dosing schedule, while edoxaban
and rivaroxaban are once daily. The short half-life
of apixaban may be of particular benefit where
abrupt withdrawal can be achieved without
worrying about sudden withdrawal effects of
bleeding.
The selection of NOACs primarily relies on
maintaining balance between efficacies and
bleeding risk (safety). The choice between the four
NOACs therefore depends on their efficacy and
safety profile. The effect of NOACs on mortality,
stroke and bleeding risks has shown some favor-
able results. NOACs provide more favorable
risk–benefit ratio compared to warfarin, and more
positive results in clinical trials. Therefore,
NOACs should generally be used as first-line
treatment for stroke prevention in AF.
However, NOACs are not always well utilized in
patients with AF. One report shows that, contrary
to current guidelines, some patients with AF are
not prescribed any NOACs [47]. This may be
attributed to the stable clinical status of some
patients, low risk of CHADS2-VASC scores, clini-
cal judgment of clinician, patient refusal, family
issues, cost, insurance issues, and other factors.
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International guidelines have recommended the
use of NOACs in line with their established safety,
efficacy and compliance [29–31]. The safety of
NOAC is supported by real world post-marketing
surveillance registry studies, such as the Danish
registry where bleeding and MI were not attribu-
ted to dabigatran [32]. In addition, reports from
the Global Registry on Long-Term Oral
Antithrombotic Treatment in Patients with Atrial
Fibrillation (GLORIA-AF) which emphasizes the
under clinical utility of NOACs, have recently
emerged. Dabigatran was coined as the most
prescribed NOAC in the Phase II registry [33,34].
The GLORIA-AF was the largest, global observa-
tional study to date on the use of anticoagulants
in patients with AF. The early reported findings
were based on treatment trends in 3415 AF
patients who entered the GLORIA-AF registry
from November 2011 to February 2014.
The GLORIA-AF results demonstrated that
21.9% of patients with occasional AF and a
CHADS2-VASC score of 2 or higher were either
undertreated with aspirin or given no anticoagu-
lant treatment at all, compared to 12.4% and
11.2% of those diagnosed with persistent or per-
manent AF, respectively [33]. Current AF guideli-
nes call for patients to receive oral anticoagulant
therapy based on their risk of stroke, rather than
their type of AF [34,35]. Furthermore, given the
availability of NOACs, guidelines state that the
use of antiplatelet therapies (such as aspirin) for
stroke prevention in AF should be limited to the
few patients who refuse any form of oral anticoag-
ulant, as the evidence for effective stroke preven-
tion from Apixaban versus acetylsalicylic acid
(ASA) is weak, with a potential for harm [35].
NOAC is the standard therapy in significantly
reducing the risk of stroke and systemic embolism
in AF patients. Physicians have diverse factors to
consider when selecting a NOAC option for
antithrombotic treatment in AF patients.
Revealing factors such as risk stratification for
bleeding, therapeutic monitoring, and renal status
may serve in bridging the treatment gap.NOAC limitations
There was no treatment evidence for NOACs in
patients with valvular AF (valves/devices). There
are other NOAC limitations, such as not having
a reversal agent in the event of bleeding.
Currently, however, antidote trials for each speci-
fic NOAC reversal are underway (Phase II and III
trials); and these include idarucizumab fordabigatran (RE-VERSE AD trial), andexanet for
apixaban-alfa (ANNEXA, Andexanet Alfa a
Novel Antidote to the Anticoagulant Effects of
factor XA Inhibitors trial) [36]. There is no
FDA-approved NOAC antidote for clinical use in
case of medical emergencies. Despite the fact that
no routine laboratory monitoring is required for
general outpatient follow-up, some laboratory
assays such as ECT and aPTT are available for
emergency situations in which patients are suffer-
ing from life-threatening bleeding. Activated
charcoal can be used to decrease the absorption
of dabigatran [37], and prothrombin complex con-
centrates (PCC) have been shown to completely
reverse the anticoagulant effect of rivaroxaban in
healthy subjects [38].
However, a recent randomized, double-blind,
placebo controlled trial of 145 healthy volunteers
demonstrated that idarucizumab, a humanized
antibody that binds dabigatran with high affinity,
could result in immediate and sustained reversal
of the anticoagulant effect [39,40]. The study
reported that idarucizumab is well tolerated
without adverse events and completely reverses
prolonged clotting time within five minutes of
administration. This was the sole specific antidote
for one of the NOACs; however, further research
is required to demonstrate its clinical utility.
In order to be implicated in clinical practice, the
following points need to be considered:
1. Clinical use according to patient need: life-threatening
hemorrhage, trauma, procedure with anticipated risk for
major bleeding.
2. Careful risk assessment will be needed as the risk for bleed-
ing outweighs the benefit of thrombo-prophylaxis.
3. Attention to fundamentals of hemostasis and supportive
measures.
4. Will the availability of NOAC antidotes drive the uptake of
NOACs?
The future of NOACs
Some gaps need to be addressed in order for
clinicians to select a NOAC and/or convert and
switch from warfarin to a NOAC. These gaps have
to be highlighted by expert opinions from the
gained meta-analysis, registries and from global
experiences who can summarize them for clini-
cians without bias or conflict of interest. This
may help solve the various controversies and dis-
parities in the clinical utility of NOACs.
The research conducted by clinicians working in
day-to-day clinical practice will be of extreme
value as their views and that of their patients
(treatment satisfaction) will provide deeper
insights into the authentic clinical utility of
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patient satisfaction and quality of life aspects of
these NOACs.
The emerging betrixaban novel once-daily fac-
tor Xa inhibitor has been shown in a small phase
II study to competitively bind to factor Xa and to
inhibit its activity. The EXPLORE-Xa study was
designed to evaluate the safety and tolerability
of betrixaban compared to warfarin in patients
with AF who are receiving or are eligible for
VKA. This phase II study of betrixaban, at doses
of 40–80 mg per day, indicated that it was well tol-
erated in AF patients at risk for stroke, with a risk
of bleeding that was similar to, or lower than, that
of well-managed warfarin. The most important
fact about this drug is its hepatic elimination,
which may provide preferences over other
NOACs in patients with renal impairment of
<30 mL/min [41].Conclusions
The messages taken from this overview can be
summarized as follows: encourage the use of
NOACs in daily clinical practice, evaluate patient
preferences, consider cost and insurance cover-
age, and select a NOAC over warfarin when over-
all clinical judgment is optimal.
Physicians need to discuss the risks and benefits
of NOACs based on patient’s clinical status and
preferences. The switch from warfarin to a
NOAC needs a selection of patients who have
shown adherence to prior anticoagulant, avoid-
ance of missed doses, and close-self monitoring
for any bleeding events.
Finally, will warfarin still be used after its 73rd
anniversary? The future undoubtedly belongs to
NOACs, and we are very grateful to warfarin, to
Karl and his senior student, but we recognize that
it is high time to say goodbye. We wish warfarin a
happy retirement and we welcome the future with
a new generation of NOACs.
Recommendations
1. Limit the use of warfarin to certain populations with pre-
defined criteria such as renal impaired patients (creatinine
clearance <30 mL/min, cost issues, insurance barriers).
2. In cases where NOACs is a suitable alternative, initiate
NOACs as per guidelines and based on the selection of
the most suitable patient groups.
3. Consider NOAC in patients intolerant to warfarin with
repeated bleeding episodes, multiple hospitalization, unpre-
dictable INR, and variable responses to warfarin dosing.
4. Concerns about risk of bleeding tendencies due to NOACs
need to be estimated in diverse populations and in varied
groups of patients with low, medium, high risk and associ-
ated co-morbidities.5. Special maneuvers (such as prophylactic proton pump inhi-
bitors) for preventing and protecting patients against
NOACs-induced risk of bleeding (or gastritis) deserve more
clinical input from physicians (awareness and enforced in
guidelines) [16].
6. Special considerations for switching patients from warfarin
to any NOACs, with strict adherence to guidelines and rec-
ommended INR threshold (<2 for initiating dabigatran/
apixaban; 63.0 for European Medical Agency-EMA; or
<3.0 for FDA for initiating rivaroxaban) [42–45].
7. Special management of patients taking NOAC (periopera-
tive) and strict emphasis on strategies to manage bleeding
complications or ‘reverse’ the anticoagulant effects for
urgent invasive procedures [46].
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